Farmaceutica R (RMAH) Fair Value & Analysis
Healthcare · RO · Market cap 74.0M RON (≈ $16.3M) · ISIN RORMAHACNOR2
What is Farmaceutica R really worth?
A solid business, trading 57% below our fair value of 1.89 RON.
Strengths
Risks
For context
Fair value as of: Aug 14, 2026
From 22 valuation models · updated 19 days ago
Fair value updated Aug 14, 2026, revised from 1.72 RON to 1.89 RON (+9.9%) since Jul 19, 2026.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price is below even our cautious bear case (1.42 RON). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 14, 2026.
How to read this chart
60‑month range 0.4206 RON – 0.9380 RON · fair‑value band 1.42 RON – 2.36 RON · the 0.8220 RON price screens below the 1.89 RON fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 14, 2026.
Analysis
Farmaceutica R (RMAH) currently trades at 0.8220 RON, while our model-based Fair Value estimate is 1.89 RON, implying the stock looks roughly 56.5% undervalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of 2.89 RON per share, and 18 of the 22 models we run sit above the 0.8220 RON price. Bear case: the Dividend Discount group reads lowest at 0.4000 RON, and 4 of the 22 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Farmaceutica R generated revenue of 740M RON at a net margin of 0.8%. Revenue declined 10.9% year over year. It earns a return on equity of 7.5%. The stock trades on a trailing P/E of 10.3. Fundamentals as of Aug 14, 2026
Our scenario range runs from 1.42 RON (bear case) to 2.36 RON (bull case); at 0.8220 RON, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 25% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 130%, RMAH screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 11 months have passed since. In that time the company retained roughly 0.0277 RON per share, which is 1.5 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 22 models by family
Widest divergence: DCF Models (2.89 RON) versus Dividend Discount (0.4000 RON). Highest evidence: FCF DCF (79).
Notify me when RMAH reaches fair value
Put RMAH on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 14, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Farmaceutica REMEDIA S.A. operates a chain of pharmacies in Romania. It is also involved in the wholesale distribution of medicines to pharmacies, and public and private hospitals and clinics.
Full company description
Farmaceutica REMEDIA S.A. operates a chain of pharmacies in Romania. It is also involved in the wholesale distribution of medicines to pharmacies, and public and private hospitals and clinics. In addition, the company provides packaging materials; and logistics and warehousing, promotion and marketing of drugs, and pharmaceutical products registration services. The company was incorporated in 1991 and is headquartered in Deva, Romania.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Farmaceutica R reported revenue of 760M RON in FY2025 versus 477M RON in FY2021, a compound +12.3%/yr. Reported net income was 8.0M RON in FY2025, compounding +2.7%/yr from FY2021.
Watch RMAH: get an alert when its fair value changes →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $896.65 | $819.31 | −9% |
| Cencora, Inc COR | $327.79 | $211.07 | −36% |
| Cardinal Health, Inc CAH | $234.55 | $141.77 | −40% |
| Henry Schein, Inc HSIC | $88.46 | $71.70 | −19% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.37 | ¥33.96 | +107% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | −24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.03 | ¥28.65 | +36% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 74.40 | kr 28.26 | −62% |
Compare Farmaceutica R with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Farmaceutica R (RMAH) overvalued or undervalued?
What is the fair value of RMAH?
What is the quality score of RMAH?
What is the revenue of Farmaceutica R (RMAH)?
What is the net profit margin of RMAH?
Does Farmaceutica R pay a dividend?
Watch Farmaceutica R in the live analysis
One click puts Farmaceutica R on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.